Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0002874 (aplastic anemia)
 5,905 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

The results for 49 patients with hematologic and non malignancies who were subjected to a cord blood transplantation from HLA-mismatched unrelated donors (UCBT) are presented here. This retrospective study included 22 patients with acute lymphoblastic leukemia, 12 with acute myelogenous leukemia, one each with chronic myelogenous leukemia, refractory anemia with myelodysplastic syndrome, and juvenile myelomonocytic leukemia, three with Wistott-Aldrich syndrome, three with adrenoleukodystrophy, two with Hunter's syndrome, one each with Hurler's syndrome, purine nucleotide phosphorylase deficiency, pure red cell aplasia, and severe aplastic anemia. In malignant diseases, the Kaplan-Meier estimates for three-year overall survival (OAS) and event-free survival (EFS) were 51.9 +/- 17.8, and 51.4 +/- 17.8%, respectively. In patients with non malignant disease, the Kaplan-Meier estimates for three-year OAS and EFS were 64.2 +/- 28.8, and 37.5 +/- 29.4%, respectively. In patients with malignancy, the HLA disparity had no effect on OAS, EFS, incidence of acute graft-versus-host disease, or engraftment. On the other hand, for engraftment, the use of UCBT from HLA-mismatched unrelated donors may require a larger study in patients with non-malignant diseases.
 ...
PMID:Cord blood transplantation from HLA-mismatched unrelated donors. 1214 82

A group of 21 consecutive patients aged 4-20 (median 13) years was prospectively allografted using a reduced intensity preparative regimen. The group included both malignant (acute lymphoblastic leukemia, acute myelogenous leukemia, and chronic myelogenous leukemia) and nonmalignant (aplastic anemia, Diamond-Blackfan anemia, thalassemia major and adrenoleukodystrophy) conditions. Follow-up times ranged between 16 and 1038 days. Four of 21 patients (9.5%) developed acute graft-versus-host disease, and 2 of them died, whereas limited chronic graft-versus-host disease was observed in 2 of 15 cases. The 100-day mortality was 19%. Median overall survival was above 1038 days, whereas the 34-month survival was 55%. These data show that reduced intensity stem cell transplantation in children permits rapid engraftment from siblings with little toxicity.
 ...
PMID:Reduced-intensity stem cell transplantation in children and adolescents: the Mexican experience. 1265 65